155 related articles for article (PubMed ID: 35339898)
21. Identification of biomarkers related to CD8
Lin J; Yu M; Xu X; Wang Y; Xing H; An J; Yang J; Tang C; Sun D; Zhu Y
Aging (Albany NY); 2020 Feb; 12(4):3694-3712. PubMed ID: 32081834
[TBL] [Abstract][Full Text] [Related]
22. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
[TBL] [Abstract][Full Text] [Related]
23. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
24. Bioinformatics analysis of C3 and CXCR4 demonstrates their potential as prognostic biomarkers in clear cell renal cell carcinoma (ccRCC).
Quan J; Bai Y; Yang Y; Han EL; Bai H; Zhang Q; Zhang D
BMC Cancer; 2021 Jul; 21(1):814. PubMed ID: 34266404
[TBL] [Abstract][Full Text] [Related]
25. New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies.
Qi Y; Wang L; Wang K; Peng Z; Ma Y; Zheng Z; Shang D; Xu W; Zheng J
Biomed Pharmacother; 2019 Mar; 111():821-834. PubMed ID: 30616081
[TBL] [Abstract][Full Text] [Related]
26. Bioinformatics analysis and verification of gene targets for renal clear cell carcinoma.
Li F; Jin Y; Pei X; Guo P; Dong K; Wang H; Chen Y; Guo P; Meng LB; Wang Z
Comput Biol Chem; 2021 Jun; 92():107453. PubMed ID: 33636636
[TBL] [Abstract][Full Text] [Related]
27. Classification of clear cell renal cell carcinoma based on
Li X; Turanli B; Juszczak K; Kim W; Arif M; Sato Y; Ogawa S; Turkez H; Nielsen J; Boren J; Uhlen M; Zhang C; Mardinoglu A
Heliyon; 2020 Feb; 6(2):e03440. PubMed ID: 32095654
[TBL] [Abstract][Full Text] [Related]
28. Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma.
Li Z; Chen Y; Hu S; Zhang J; Wu J; Ren W; Shao N; Ying X
Oncotarget; 2016 Dec; 7(50):82671-82685. PubMed ID: 27705920
[TBL] [Abstract][Full Text] [Related]
29. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
30. A 44-gene set constructed for predicting the prognosis of clear cell renal cell carcinoma.
Wang Y; Wang Y; Liu F
Int J Mol Med; 2018 Dec; 42(6):3105-3114. PubMed ID: 30272265
[TBL] [Abstract][Full Text] [Related]
31. A five-gene methylation signature predicts overall survival of patients with clear cell renal cell carcinoma.
Jing X; Xu G; Gong Y; Li J; LingfengWu ; Zhu W; He Y; Li Z; Pan S
J Clin Lab Anal; 2021 Dec; 35(12):e24031. PubMed ID: 34716619
[TBL] [Abstract][Full Text] [Related]
32. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
[TBL] [Abstract][Full Text] [Related]
33. Traditional Chinese medicine Bu-Shen-Jian-Pi-Fang attenuates glycolysis and immune escape in clear cell renal cell carcinoma: results based on network pharmacology.
Zheng J; Xu W; Liu W; Tang H; Lu J; Yu K; Song X; Li F; Wang Y; Wang R; Chen L; Zhang H; Qiu Y; Wei G; Zhou X; Yang J
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34002799
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma.
Shen C; Liu J; Wang J; Zhong X; Dong D; Yang X; Wang Y
Int Immunopharmacol; 2020 Apr; 81():106274. PubMed ID: 32044664
[TBL] [Abstract][Full Text] [Related]
35. Network neighborhood operates as a drug repositioning method for cancer treatment.
Cüvitoğlu A; Isik Z
PeerJ; 2023; 11():e15624. PubMed ID: 37456868
[TBL] [Abstract][Full Text] [Related]
36. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
37. MD-Miner: a network-based approach for personalized drug repositioning.
Wu H; Miller E; Wijegunawardana D; Regan K; Payne PRO; Li F
BMC Syst Biol; 2017 Oct; 11(Suppl 5):86. PubMed ID: 28984195
[TBL] [Abstract][Full Text] [Related]
38. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
39. Identifying prognostic features by bottom-up approach and correlating to drug repositioning.
Li W; Yu J; Lian B; Sun H; Li J; Zhang M; Li L; Li Y; Liu Q; Xie L
PLoS One; 2015; 10(3):e0118672. PubMed ID: 25738841
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis.
Zhou L; Liu S; Li X; Yin M; Li S; Long H
Mol Med Rep; 2019 May; 19(5):3485-3496. PubMed ID: 30896867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
